SOURCE: Paragon Financial Limited

Paragon Financial Limited

November 28, 2011 08:16 ET

Advanced Cell Technology and Cytori Therapeutics Gain Support as Geron Changes Strategy

The Paragon Report Provides Equity Research on Advanced Cell Technology & Cytori Therapeutics

NEW YORK, NY--(Marketwire - Nov 28, 2011) - The stem cell industry lost one of its key players earlier this month when industry pioneer, Geron Corporation announced its intention to exit the stem cell research market. The company, which was a leader in stem cell research, intends to focus on its oncology programs instead. Geron's exit has left not only the stem cell industry more wide open, but also the spinal cord injury treatment sector. The Paragon Report examines investing opportunities in the Biotechnology Industry and provides equity research on Advanced Cell Technology, Inc. (OTCBB: ACTC) and Cytori Therapeutics, Inc. (NASDAQ: CYTX). Access to the full company reports can be found at:

Geron didn't cite any clinical or scientific setbacks. The company said one stem-cell therapy had been well-tolerated in a small clinical trial of people with spinal-cord injuries -- the first such trial cleared by US regulators. That trial is being halted, however. Geron also suggested its stem-cell program would be attractive for another company to pick up.

The Paragon Report provides investors with an excellent first step in their due diligence by providing daily trading ideas, and consolidating the public information available on them. For more investment research on the biotechnology industry register with us free at and get exclusive access to our numerous stock reports and industry newsletters.

Geron's withdrawal leaves Advanced Cell Technology as the only publically traded company now conducting a clinical trial involving human embryonic stem cells, The New York Times reports. Embryonic stem cells can turn into virtually any type of tissue in the body, so some doctors are hopeful they might one day be used to create replacement cells or tissues to fight a vast array of diseases.

Advanced Cell Technology recently announced that the independent Data and Safety Monitoring Board (DSMB) overseeing the Company's two ongoing stem cell clinical trials in the United States authorized ACT to move forward with enrolling and treating the next set of patients in each of the trials.

Cytori is a leader in cell therapy, providing patients and physicians around the world with medical technologies that harness the potential of adult regenerative cells from adipose tissue. The company recently announced that revenues for the third quarter of 2011 increased to $2.1 million, compared to $1.5 million in the third quarter of 2010.

The Paragon Report has not been compensated by any of the above-mentioned publicly traded companies. Paragon Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at